Methods and compositions for treating hepatitis C virus
AssigneesIdenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari
InventorsJean-Pierre Sommadossi, Paulo LaColla
Life of this patent
Estimating the term…
Abstract
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
Claims15
A method for the treatment of a hepatitis C virus infection in a host, comprising contacting a cell infected with a hepatitis C virus an effective amount of a compound of the formula:
- or a mono-, di- or tri-phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, wherein
- R1′, R2 and R3 are each independently H;
- phosphate or a stabilized phosphate prodrug;
- acyl;
- or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1′, R2 or R3 is independently H or phosphate;
- Y is hydrogen;
- bromo;
- chloro, fluoro;
- iodo;
- OR4;
- NR4R5 or SR4;
- X1 and X2 are each independently H;
- straight chained, branched or cyclic alkyl;
- CO-alkyl;
- CO-aryl;
- CO-alkoxyalkyl;
- chloro;
- bromo;
- fluoro;
- iodo;
- OR4;
- NR4R5 or SR5;
- and R4 and R5 are independently hydrogen;
- acyl;
- or alkyl.
A method for the treatment of a hepatitis C virus infection in a host, comprising contacting a cell infected with a hepatitis C virus an effective amount of a compound of the formula:
- or a mono-, di- or tri-phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, wherein
- R1, R2 and R3 are each independently H;
- phosphate or a stabilized phosphate prodrug;
- acyl;
- or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
- Y is hydrogen;
- bromo;
- chloro, fluoro;
- iodo;
- OR4;
- NR4R5 or SR4;
- X1 is H;
- straight chained alkyl;
- branched alkyl;
- cyclic alkyl;
- CO-alkyl;
- CO-aryl;
- CO-alkoxyalkyl;
- chloro;
- bromo;
- fluoro;
- iodo;
- OR4;
- NR4R5 or SR5;
- and R4 and R5 are independently hydrogen;
- acyl;
- or alkyl.
A method for the treatment of a hepatitis C virus infection in a host, comprising administering to the host infected with a hepatitis C virus an effective amount of a compound of the formula:
- or a mono-, di- or tri-phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, wherein
- R1′, R2 and R3 are each independently H;
- phosphate or a stabilized phosphate prodrug;
- acyl;
- or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1′, R2 or R3 is independently H or phosphate;
- Y is hydrogen;
- bromo;
- chloro, fluoro;
- iodo;
- OR4;
- NR4R5 or SR4;
- X1 is H;
- straight chained alkyl;
- branched alkyl;
- cyclic alkyl;
- CO-alkyl;
- CO-aryl;
- CO-alkoxyalkyl;
- chloro;
- bromo;
- fluoro;
- iodo;
- OR4;
- NR4R5 or SRS;
- and R4 and R5 are independently hydrogen;
- acyl;
- or alkyl.
Dependencies are inferred from the claim text.